Table 1.

T22-PE24-H6 antimetastatic effect measured by prevention of metastases development in the CXCR4⁺ SW1417 cell-derived CRC metastatic model.

T22-PE24-H6 prevention of metastasis
SW1417 cell-derived orthotopic model
Group	Primary tumor	Lymph node Mets	Liver Mets	Lung Mets	Peritoneal Mets
	Mice %	Mice % # foci	Mice % # foci	Mice % # foci	Mice % # foci
Buffer	9/9 100%	100%	100%	100%	89%
		7.1 ± 1.1a	15 ± 1.9b	49.2 ± 9.6c	4.4 ± 0.7
T22-PE24-H6	9/9 100%	100%	100%	89%	89%
		3.4 ± 0.5a	7.1 ± 1.6b	19.7 ± 4.1c	3.2 ± 0.9
Metastatic foci size (µm² × 103)
Group	Primary tumor	Lymph nods Mets	Liver Mets	Lung Mets	Peritoneal Mets
Buffer	9428.8 ± 1081.1	739.8 ± 94.6	15.7 ± 3.5	44.1 ± 9.1	2423.4 ± 1141.2
T22-PE24-H6	7331.5 ± 978.8	513.8 ± 99.3	16.5 ± 4.2	36.1 ± 8.9	2579.2 ± 1345.9

Mean + s.e.m. metastatic foci number or area (µm²) per mouse, counted in three entire histology sections.

^ap = 0.008; ^bp = 0.007; ^cp = .001.